Ton Logtenberg

Ton Logtenberg is a founder, President and Chief Executive Officer of Merus N.V., a Nasdaq-listed Immuno-oncology company headquartered in Utrecht, The Netherlands. Ton also co-founded Crucell N.V., serving as its Executive Vice President and Chief Scientific Officer from 2000 until 2003. In 2016, he was appointed professor of Biomedical Entrepreneurship at Utrecht University and serves as a member of the board of directors of the Jenner Foundation, a member of the supervisory board of Utrecht Science Park and a member of the supervisory board of the Foundation Hubrecht Organoid Technology. Prof. Logtenberg holds a Ph.D. in medical biology from Utrecht University.

October 18, 2019 CrownBio launched patient-derived tumor organ... San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development pl... read more
October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more
July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more